Bristol Tries Out New Selling Strategy With Yervoy Launch
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
You may also be interested in...
IQWiG of Germany has rejected Bristol/AstraZeneca’s Komboglyze for diabetes type 2 on procedural grounds, including use of the wrong comparator. The watchdog’s decision should induce manufacturers to negotiate early with health technology assessment bodies.
The first-in-class immunotherapy for metastatic melanoma generated $95 million in its first full quarter on the market, exceeding management's expectations.
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.